Should Patient with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) be vaccinated with COVID-19 Vaccines?

Autor:	Anna Ariane, Andi Raga Ginting, Perdana Aditya, Sumariyono Sarmidi, Lisa Kurnia Sari, Harry Isbagjo, Herlina Yani, Faisal Parlindungan, Cesarius Singgih Wahono, Rudy Hidayat, Ika Vemilia, Rm. Suryo Anggoro Kw, Ratih Manuaba, Pande Ketut Kurniari
Rok vydání:	2021
Předmět:	Vaccination Attenuated vaccine Increased risk Coronavirus disease 2019 (COVID-19) business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Immunology Medicine Disease Inflammatory rheumatic disease business
Zdroj:	Indonesian Journal of Rheumatology; Vol. 13 No. 1 (2021): Indonesian Journal of Rheumatology; 492-503
ISSN:	2581-1142 2086-1435
DOI:	10.37275/ijr.v13i1
Popis:	Vaccination is a very important measure for the prevention of various infections worldwide including the recent COVID-19 disease. However, until now the COVID-19 vaccine with various platforms has not been clinically tested on autoimmune inflammatory rheumatic disease (AIIRD) patients, due to caution against possible side effects and unknown efficacy. Several recent studies proved that there is increased risk of SARS-CoV-2 infection in AIIRD patients and moreover, those patients also have worse COVID-19 outcomes. Thus, patients with AIIRD should be prioritized for vaccination because they have an increased burden of infections, including COVID-19. Many studies showed that inactivated/non-live vaccine is safe for AIIRD patients and do not cause disease exacerbations. We conclude that benefits of vaccination greatly outweigh the risks of infection and therefore, COVID-19 vaccines can also be administered safely in stable AIIRD patients.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5319079536b8802e91bdf0cd78fe8437 https://doi.org/10.37275/ijr.v13i1.167 Zobrazit plný text záznamu